The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015.
Dr. Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako AS, followed by Ostemeter AS (CEO), Torsana Biosensor AS (CEO), Celtor Biosystems Inc (EVP), Combio AS (CEO), Natimmune AS (CEO), Aros Pharma ApS (CEO) and most recently Epitherapeutics Aps now sold to Gilead (CEO). His experience includes a significant number of transactions within business development, trade sales, mergers & acquisitions as well as management of research and development.
Dr. Bonde holds a Ph.D. in Immunochemical Techniques and a Master of Science in Chemical Engineering from the Technical University of Denmark as well as a Bachelor of Commerce in International Economy from Copenhagen Business School.
Tom Pike, Chairman of Vaccibody, says, "We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin's extensive track record in deal making. We also believe that our ability to attract an experienced industry executive with Martin's credentials reflect positively on Vaccibody's` considerable potential".
About Vaccibody AS
Vaccibody is a biopharmaceutical company dedicated to the discovery and development of novel immunotherapies and vaccines which target cancer and infectious diseases, for human and veterinary use. Vaccibody's internal lead program is focused on VB10.16, a therapeutic DNA vaccine against HPV induced pre-malignancies and malignancies. Vaccibody also offers its proprietary Vaccibody technology to other pharmaceutical companies for the improvement of their immunotherapy and vaccines. In 2014 the company announced one such agreement with the global veterinarian company Phibro Animal Health, for the development of vaccines for poultry.